Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
223
resultados
Última actualización
02/11/2026 [07:28:00]
Resultados 25 a 50 de 223
Resumen de: CN122998092A
本发明涉及一种J聚集体Pt杂化肖特基异质结双功能纳米材料及其制备方法和应用，由BDP光热分子与DSPE‑PEG2000组装为J聚集体Agg，负载Pt纳米粒子制得肖特基异质结双功能纳米材料Agg/Pt。该材料在808 nm激光下具有高效光热转化性能，可通过局部过热杀死肿瘤细胞，但单纯高热易损伤肿瘤周边正常细胞并诱发过度免疫。在超声刺激下可高效催化产H2、分解瘤内H2O2供氧并消耗GSH。H2可差异调控细胞内ROS，促进肿瘤细胞氧化应激损伤，发生免疫原性死亡；维持正常细胞氧化还原稳态，从而缓解光热副作用。为肿瘤氢热联合治疗提供了一种新的思路与方法。
Resumen de: CN122998096A
本发明公开了一种复方苦参汤纳米颗粒递送系统及其制备方法和应用，属于生物医药技术领域。该制备方法具体包括以下步骤：（1）复方苦参汤纳米颗粒的制备；（2）透明质酸修饰；（3）阴离子型甲基丙烯酸共聚物包覆。本发明系统能够在胃及小肠上段环境中保持相对稳定，减少活性成分提前释放；到达回肠末端及结肠较高pH环境后，Eudragit S100外层发生结构解离，释放内部透明质酸修饰的复方苦参汤纳米颗粒，实现药物结肠定位释放；随后，透明质酸通过与炎症相关细胞表面高表达CD44受体特异性结合，促进纳米颗粒在结肠炎症区域的黏附、滞留和细胞摄取，从而解决复方苦参汤传统给药方式中结肠靶向性不足和病灶富集效率低的问题。
Resumen de: CN122998094A
本发明适用于生物技术领域，提供了一种用于缓解晕动症的滴鼻制剂及其制备方法和应用，该滴鼻制剂以小鼠海马神经元细胞系HT22来源的外泌体为载体，通过超声法装载L‑薄荷醇制备而成，本发明采用滴鼻给药方式，可经鼻腔黏膜‑嗅神经通路直接入脑，精准靶向晕动症相关脑区，避免胃肠道消化和肝脏首过效应，具有成分安全、副作用小、起效迅速、使用方便且具有缓释功能的优点。
Resumen de: US20260335249A1
The present disclosure relates, in one aspect, to ionizable lipids of Formula (I). In another aspect, the present disclosure relates to the preparation of ionizable lipids of Formula (I). In other aspects, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of Formula (I), at least one neutral lipid, cholesterol, and at least one conjugated lipid, and methods of use thereof.
Resumen de: WO2026222821A1
Disclosed in the present invention are a triboelectric-responsive DNA hydrogel dressing for promoting wound healing, a preparation method therefor, and use thereof. The hydrogel can simultaneously load silver nanoclusters, VEGF, and diclofenac sodium by means of a DNA three-way junction structure containing a cytosine ring, a DNA linker containing a VEGF aptamer sequence, and a cross-linked backbone deposited by polypyrrole. The DNA hydrogel dressing prepared in the present invention utilizes the triboelectric-responsive properties to achieve on-demand drug delivery and promote the healing of bacteria-infected diabetic wounds, and has characteristics such as good biocompatibility, excellent antibacterial performance, fast response speed, and remarkable healing effect. Moreover, the preparation process is simple, low in cost, and easy for large-scale production. Therefore, the present invention helps to solve the problems of insufficient antibacterial performance, poor electrical conductivity, and low healing efficiency of existing wound dressings, and can further expand its application in the treatment of chronic wounds and diabetic wounds, thereby providing an important solution for wound care and infection control.
Resumen de: US20260335462A1
Provided herein are lipid nanoparticle compositions comprising a cationic lipid, a steroid, a polymer conjugated lipid, and no more than 0.5 mole percent phospholipid, that can be used for delivery of therapeutic payloads (e.g., mRNA, siRNA, DNA) for therapeutic or prophylactic purposes.
Resumen de: US20260335359A1
The present invention relates to a composition for cancer immunotherapy, comprising superparamagnetic nanoparticles as an active ingredient, a composition for treating immune diseases, a composition for enhancing immunity, a composition for suppressing a decrease in immune function or enhancing immune function, the composition being administered in combination with a chemotherapeutic anticancer drug, a composition for suppressing a decrease in immune function, caused by anticancer treatment or enhancing immune function, and a composition for ameliorating, treating or preventing decreased immune responses in individuals with cancer. The superparamagnetic nanoparticles according to the present invention have magnetically-induced heating characteristics and high biocompatibility, thus being applicable through in vivo injection, and can induce an increase in immune cells, thus being effectively used in the treatment of cancer and immune diseases.
Resumen de: US20260335248A1
This application relates generally to methods of treating or preventing mucormycosis in a subject in need thereof using, inter alia, encochleated oral formulations of amphotericin B.
Resumen de: US20260335376A1
A composition of matter for treating inflammatory bowel diseases (IBDs) and a corresponding method for treating IBDs. The composition of matter includes a reactive oxygen species (ROS) scavenger conjugated to a probiotic. The method includes administering the composition of matter to a subject in an anti-IBD-effective amount.
Resumen de: US20260335351A1
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Resumen de: US20260335287A1
Method and compositions that comprise an agent that reduces nNOS activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.
Resumen de: AU2026253888A1
METHOD FOR TREATING OSTEOARTHRITIS WITH A COMBINATION OF MESENCHYMAL STEM CELL EXOSOMES, SYNOVIAL MESENCYMAL STEM CELLS, AND SCAFFOLDS Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device; covering articular cartilage in an affected joint with a scaffold; and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells. ct c t
Resumen de: US20260335447A1
Disclosed herein are DNA origami nanostructure that can be functionalized for personalized and targeted drug delivery. The disclosed nanostructures enter cells through the endolysosomal pathway and circumvent drug resistance mechanisms in target cells. The disclosed nanostructures can be loaded small molecule drugs (e.g. anthracyclines, anti-metabolites) and nucleic acids (e.g. antisense oligonucleotides, siRNA, miRNA) with targeting and/or therapeutic antibodies against tumor-specific antigens (e.g. anti-CD33, anti-CD20) that can be modified to treat to a wide range of cancers and ultimately tailored to specific patients' needs for precision medicine.
Resumen de: US20260335405A1
Described herein are compositions and methods useful for treating autoimmune diseases and inflammatory disorders. The compositions and methods utilize ubiquitous, non-tissue specific antigens associated with major histocompatibility complexes (MHCs) and coupled to a nanoparticle core to induce regulatory T cells and regulatory B cells.
Resumen de: US20260337552A1
Embodiments of systems, methods, and compositions provided herein relate to hollow encapsulating single cells. Some embodiments include performing multiple co-assays single cell encapsulated within a hollow bead, including nucleic acid sequencing, preparing nucleic acid libraries, determining methylation status, identifying genomic variants, or protein analysis.
Resumen de: US20260337294A1
The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.
Resumen de: US20260337150A1
The present invention concerns a lipid of formula (I), a composition comprising said lipid of formula (I), a process for manufacturing said lipid of formula (I) and/or said composition, the lipid of formula (I) and/or the composition for its use as a medicament, the use of said lipid of formula (I) and/or of said composition as a vector for delivering an active ingredient to subject(s), organ(s), cell(s) and/or tissue(s). a method for transfecting cells with a nucleic acid and/or a protein and/or a peptide and/or a polysaccharide and/or a lipid and/or a small organic or inorganic molecule and/or any type of bioactive molecule using said lipid of formula (I) and/or said composition, transfected cells obtained by said method, and a kit comprising said lipid of formula (I) and/or said composition.
Resumen de: US20260337153A1
The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Resumen de: US20260337637A1
The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating hemoglobinopathies, including sickle cell disease and beta-thalassemia. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics to red blood cell progenitor cells, enabling treatment of hemoglobinopathies, in vivo.
Resumen de: US20260335366A1
Disclosed are methods for treating muscle wasting diseases, such as spinal muscular atrophy, or muscular dystrophies, using matrix bound vesicles (MBV). Compositions for use in treating a muscle wasting disease are also disclosed.
Resumen de: WO2026227084A1
A method of synthesising gold nanoparticles for treating breast cancer is provided The gold nanoparticles are synthesised by a process which comprises adding an aqueous Dodonaea viscosa leaf extract to a solution containing gold ions, such as gold (III) chloride hydrate. Phytochemicals in the aqueous extract reduce the gold ions, leading to the formation of gold nanoparticles which are capped with compounds from the extract. The nanoparticles are stable and are capable of inhibiting the growth of breast cancer cells in vitro and significantly reducing tumour size in vivo, while having little effect on non-cancerous cells. Gold nanoparticles produced by the method, a composition comprising the gold nanoparticles and a method of treating breast cancer are also described.
Resumen de: WO2026222691A1
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules encoding gene editing machinery) for therapeutic or prophylactic purposes.
Resumen de: WO2026226739A1
The present disclosure provides a nanoparticle complex comprising (a) a lipid nanoparticle comprising a non-sheddable surface component and a sheddable surface component, and (b) a bifunctional binder comprising a self-binder moiety non-covalently binding to the non-sheddable surface component and a target-binder moiety capable of binding to a targeted cell-surface component of a target cell.
Resumen de: WO2026226118A1
The invention relates to the production of biocompatible nanocomposites containing eggshell and zinc oxide (ZnO) nanoparticles by a single-step green synthesis method. In the production process, plant extract prepared from flowers of Althaea officinalis having high quercetin content and powdered eggshell are combined with zinc nitrate solution to obtain the nanocomposite. The material obtained by this innovative production method has a wide potential of use in medical devices, implants, wound dressings, food packaging and environmental applications.
Nº publicación: US20260335420A1 29/10/2026
Solicitante:
MODERNATX INC [US]
ModernaTX, Inc.
Resumen de: US20260335420A1
This disclosure provides methods and compositions related to messenger ribonucleic acid (mRNA) vaccines for Lyme disease and related methods of prevention. The mRNA vaccines comprise an mRNA comprising an open reading frame(s) encoding for a protein comprising a Borrelia outer surface protein A (OspA) extracellular domain. In some aspects of the disclosure, the mRNA vaccines comprise mRNA polynucleotides collectively encoding for at least seven different Borrelia outer surface protein A (OspA) extracellular domains.
BOPI
Sede Electrónica
